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To examine the long-term infectivity of human norovirus in water, 13 study subjects were challenged at
different time points with groundwater spiked with the prototype human norovirus, Norwalk virus. Norwalk
virus spiked in groundwater remained infectious after storage at room temperature in the dark for 61 days (the
last time point tested). The Norwalk virus-seeded groundwater was stored for 1,266 days and analyzed, after
RNase treatment, by reverse transcription-quantitative PCR (RT-qPCR) to detect Norwalk virus RNA con-
tained within intact capsids. Norwalk virus RNA within intact capsids was detected in groundwater for 1,266
days, with no significant log10 reduction throughout 427 days and a significant 1.10-log10 reduction by day 1266.
Purified Norwalk virus RNA (extracted from Norwalk virus virions) persisted for 14 days in groundwater, tap
water, and reagent-grade water. This study demonstrates that Norwalk virus in groundwater can remain
detectable for over 3 years and can remain infectious for at least 61 days. (ClinicalTrials.gov identifier
NCT00313404.)
Human noroviruses (HuNoV) are nonenveloped, single-
stranded RNA viruses that spread primarily through the fecal-
oral route (reviewed in references 11, 16, and 17). They are the
primary cause of epidemic gastroenteritis worldwide (5, 11, 27)
and are estimated to cause 218,000 deaths and 1.1 million
hospitalizations among children in developing countries each
year (27). Water is an important route of HuNoV transmission
(11), and HuNoV are considered a significant cause of water-
borne gastroenteritis worldwide (5, 37). To reduce the risk of
waterborne HuNoV outbreaks, it is necessary to understand
HuNoV infectivity and persistence in water.
HuNoV is highly resistant to environmental degradation in
various water types. Due to the lack of a simple infectivity assay
for HuNoV, previous studies have utilized molecular detection
techniques to study HuNoV persistence in water. HuNoV was
detectable in mineral water at 4 and 25°C up to 100 days by
reverse transcription-quantitative PCR (RT-qPCR) (26) and
in groundwater at 12°C for 728 days by conventional PCR (8).
We previously calculated the nucleic acid reduction rate of the
prototype HuNoV, Norwalk virus (NV), at 25°C to be 0.08 
0.02 log10/day in surface water and 0.01  0.05 log10/day in
groundwater (3). However, molecular detection of HuNoV
does not directly imply infectivity; for example, RT-PCR can
detect both RNA released from viral capsids (presumably non-
infectious) and RNA within viral capsids (potentially infec-
tious) (35). Although infectivity assays with HuNoV surrogates
(e.g., murine norovirus, feline calicivirus, and poliovirus) have
been used to estimate HuNoV infectivity in water (3), the
comparability of viral surrogate infectivity to HuNoV infectiv-
ity remains uncertain. Additional research has focused on the
resistance of the HuNoV capsid to environmental degradation
(29), yet little information exists on the persistence of purified
or partially exposed HuNoV RNA in water.
In the present study, we conducted a blinded human clinical
trial to measure the duration of the infectivity of NV in
groundwater. Furthermore, we quantitatively analyzed the
long-term persistence of potentially infectious NV in ground-
water (in years) and purified NV RNA in various water types
(in weeks).
MATERIALS AND METHODS
Study subjects. Study subjects were recruited from Atlanta, GA, from May
2006 to December 2006 and provided informed consent before the screening.
Eligible volunteers were 18 to 50 years old, in good health (determined by a
clinical evaluation), and secretor status positive (secreted carbohydrate H type 1,
the putative NV receptor [19]). Exclusion criteria included having an enteric
infection within 1 month of enrollment and pregnancy (determined by a preg-
nancy test). This clinical trial was approved by the Emory University Institutional
Review Board and is registered on ClinicalTrials.gov (identifier NCT00313404).
Secretor status determination. Secretor status was assessed by enzyme-linked
immunosorbent assay (ELISA) as previously described (2). We modified the
method by using polystyrene Costar enzyme immunoassay/radioimmunoassay
(EIA/RIA) flat-well, medium binding plates (Corning, Lowell, MA), 0.1% un-
processed saliva in phosphate-buffered saline (PBS) (Lonza, Walkersville, MD)
(incubated overnight at 4°C), and 1 mg/ml horseradish peroxidase (HRP)-con-
jugated rabbit anti-UEA-I antibody (EY Laboratories, San Mateo, CA) diluted
to 0.2% in PBS (Lonza, Walkersville, MD) containing 5% nonfat milk (Blotto for
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Western analysis/ELISA; Alpha Diagnostic Intl., San Antonio, TX). Reactions
were developed with tetramethylbenzidine substrate (BioFX, Owings Mills, MD)
and quenched with 0.18 M hydrochloric acid (Fisher Scientific, Pittsburgh, PA).
The optical density at 450 nm (OD450) of each well was read using the SmartSpec
Plus spectrophotometer (BioTek, Winooski, VT) and KCjunior software
(BioTek, Winooski, VT). Secretor-positive samples were defined as having an
average OD450 value that was 4 times that of the negative control (a secretor-
negative saliva sample).
Groundwater collection and spiking. Groundwater (1 liter) was collected from
a residential well in Atlanta, GA (previously characterized in reference 3). An
independent laboratory (Gel Laboratories, Cincinnati, OH) assayed a water
sample from this untreated groundwater to determine whether it met U.S.
Environmental Protection Agency (USEPA) drinking water standards and found
that levels of chemical pesticide residue were slightly higher than USEPA drink-
ing water guidelines. After we passed the groundwater samples through a Brita
(The Brita Products Company, Oakland, CA) cartridge (combination of ion-
exchange resin and activated carbon) twice, the independent laboratory con-
firmed the water sample met USEPA drinking water standards, and we were able
to safely administer it to human subjects. The groundwater sample was frozen in
50-ml aliquots. For each human challenge, a 50-ml groundwater aliquot was
thawed, and 9 ml of the groundwater was combined with 1 ml of 8FIIb NV
inoculum (HuNoV genogroup GI.1) (34) to a final concentration of 6.5  107
NV genomic equivalent copies per milliliter (GEC/ml). This seeded groundwater
was stored in the dark at room temperature for a set time.
Clinical trial. A total of 13 of 23 screened subjects were enrolled in the clinical
trial. A total of 46% of enrolled subjects were male, 62% were Caucasian, and
38% were African-American. The only significant protocol deviation was one
missed follow-up appointment, and this did not prevent assessment of the pri-
mary outcome of NV infection. There were no unexpected study-related adverse
events.
Before challenge, 10 ml of the seeded groundwater (6.5  108 NV GEC) was
added to 90 ml of distilled water. Study subjects (n  13) ingested the 100-ml
water sample at Emory University Hospital’s General Clinical Research Center.
Subjects were blinded to the amount of time the NV-seeded groundwater was
stored before challenge. Each subject ingested 100 ml of 2% sodium bicarbonate
solution 2 min before and 5 min after challenge to neutralize gastric acidity
(consistent with previous HuNoV challenge studies [9, 12, 18, 19]). Symptom
information, stool, emesis, and blood samples were collected daily during a 5-day
hospital stay and at outpatient visits on approximately 8, 14, 21, 28, and 35 days
postchallenge. Blood samples were centrifuged (centrifuge 5810 R, rotor A-4-81;
Eppendorf, Hamburg, Germany) at 25°C at 1,600  g for 20 min, and the sera
were stored at 80°C. NV infection was defined as seroconversion (4-fold
increase in NV-specific serum IgG titer in any postchallenge versus prechallenge
serum sample) (19) or the presence of NV RNA, detected by RT-PCR, in any
postchallenge stool or emesis sample.
Seroconversion and viral shedding determination. NV-specific serum IgG was
quantified by ELISA as previously described (19). For RT-PCR, 100 l of stool
or emesis samples was suspended in 400 l of reagent-grade water (Cellgro,
Manassas, VA), added to 500 l of Vertrel XF (DuPont, Wilmington, DE), and
centrifuged (centrifuge 5415 R, rotor F-45-24-11; Eppendorf, Hamburg, Ger-
many) at 25°C at 13,000  g for 10 min. RNA was extracted from the supernatant
by following the QIAamp viral RNA minikit vacuum protocol (Qiagen, Valencia,
CA), except that 50 l of reagent-grade water (Cellgro, Manassas, VA) was used
for the elution step and emesis samples were concentrated five times through one
filter. The Qiagen columns that we used have been shown to remove RT-PCR
inhibitors from stool samples (1, 6). RT-PCR was performed with NV primer
pair 51-3 as previously described (25, 36) with the following modifications: a
20-l reverse transcriptase (RT) mixture was made with 4.5 U AMV reverse
transcriptase (Promega, Madison, WI), 4.0 l of 5 Green GoTaq reaction
buffer (Promega, Madison, WI), 20 U RNase inhibitor (Promega, Madison, WI),
0.25 mM deoxynucleoside triphosphate (dNTP) mixture (Qiagen, Valencia, CA),
5.63 M primer 51 (Sigma, St. Louis, MO), 1.5 l of Triton X-100 (Alfa Aesar,
Ward Hill, MA), and 5 l of stool- or emesis-extracted RNA. PCR modifications
included an initial denaturation for 3 min and the addition of a 30-l PCR
mixture to create a final 50-l reaction volume containing 1.25 U GoTaq DNA
polymerase (Promega, Madison, WI), 6 l of 5 Green GoTaq reaction buffer
(Promega, Madison, WI), and 2.25 M primer 3 (Sigma, St. Louis, MO). Gel
electrophoresis and sample analysis were performed as described previously (25).
Part of the dose used to challenge one pair of volunteers was stored at room
temperature in the dark for 1,266 days. Specifically, 27 ml of the groundwater was
combined with 3 ml of 8FIIb NV inoculum (HuNoV genogroup GI.1). Of this
dose, 20 ml (10 ml per volunteer) was used to dose a pair of volunteers, and the
remaining 10 ml was stored at room temperature in the dark for 1,266 days.
Fifty-microliter aliquots were removed at 0, 7, 14, 21, 35, 413, 441, 622, and 1,266
days and frozen at 80°C. Results from two to five 50-l aliquots are presented.
All of the aliquots were thawed and tested by RT-qPCR. To extract NV RNA,
3 l of each aliquot was added to 26.4 l of reagent-grade water (Cellgro,
Manassas, VA) and 0.6 l of RNase inhibitor (Promega, Madison, WI), heated
to 99°C for 5 min, and chilled on ice for 2 min (22). Three or four additional
50-l aliquots were removed at 0, 427, and 1,266 days and frozen at 80°C.
These aliquots were treated with RNase before RNA extraction to degrade RNA
released from damaged viral capsids (presumably noninfectious). For RNase
treatment, 3 l of each aliquot was incubated with 1 l of RNase One (Promega,
Madison, WI) diluted in 26.4 l of reagent-grade water (Cellgro, Manassas, VA)
at 37°C for 15 min. After addition of 0.6 l of RNase inhibitor (Promega,
Madison, WI), viral RNA was extracted by heating, as described above. To
obtain the average concentration of NV GEC/l for each time point, all of the
aliquots were analyzed in duplicate in several runs by RT-qPCR using DNA
standards as previously described (23), except for an elongation temperature of
60°C for 30 s. The detection limit for the RT-qPCR assay is 20 genomic equiv-
alent copies per reaction (22). This detection limit corresponds to a 2.57-log10
reduction or greater without RNase treatment and a 1.16-log10 reduction or
greater with RNase treatment (determined by taking the log10 of the detection
limit [20 genomic equivalent copies per reaction] divided by the average con-
centration of genomic equivalent copies at day 0 for each experiment).
In the purified NV RNA persistence experiments, NV RNA was extracted
from the stool of an 8FIIb NV-infected volunteer (34) as described above. A
total of 150 l of the purified NV RNA extracted from NV virions was added to
1.35 ml of Georgia groundwater (passed twice through a Brita [The Brita Prod-
ucts Company, Oakland, CA] cartridge), tap water (collected from laboratory
faucets after running for 5 min; approximately 0.42 mg/liter of free chlorine,
measured by a model 1200 single-test colorimeter [LaMotte, Chestertown,
MD]), and reagent-grade water (Cellgro, Manassas, VA) to a final concentration
of 8  104 NV GEC/l. The seeded water samples were stored in the dark at
room temperature. To obtain the average concentration of NV GEC/l for each
time point, two 37.5-l aliquots at each time point (0, 7, and 14 days) were
analyzed in duplicate in one single run by RT-qPCR as described above, except
for the use of RNA standards (22). The results are representative of 5 separate
experiments. The limit of detection corresponds to a 3.60-log10 reduction or
greater.
The number of replicate results for each time point varied because some
replicates failed quality control assays (e.g., threshold cycle [CT] values for
standards were not consistent, controls did not work, etc.), replicates could not
be reused, and we were limited by the original number of replicates collected for
each assay. However, for all of the assays, each aliquot per run was assayed in
duplicate, resulting in at least 4 to 10 assays for each sample and time point to
obtain the average concentrations in NV GEC/l.
Statistical analysis. Data were double entered into Microsoft Excel 2007
(Microsoft Corporation, Redmond, WA), cleaned to resolve discrepancies, and
analyzed in SAS 9.2 (SAS Institute, Cary, NC). To avoid underrepresentation
and overrepresentation of RT-qPCR values, when values fell below the detection
limit, values were assigned one-half of the RT-qPCR detection limit (22, 30).
Significant differences between groups were analyzed by the Mann-Whitney test
(2 comparisons) or the Kruskal Wallis test, followed by Dunnett’s test (2
comparisons). A P value of 0.05 was considered significant.
RESULTS
NV in groundwater can remain infectious for at least 61
days. After ingesting stored NV-seeded groundwater, 10 of 13
subjects became infected with NV and experienced a range of
viral shedding and clinical symptoms (Table 1). Ingestion of
NV-seeded groundwater stored for 61 days (the longest time
point tested) caused infection in 2/2 study subjects (Fig. 1).
NV in groundwater can remain detectable for over 3 years.
NV in groundwater was detected by RT-qPCR for 1,266 days
postseeding (last sampling date). Compared to day 0, there was
no significant NV log10 reduction after 622 days of storage, but
there was a significant 1.79-log10 reduction by day 1266 (Fig.
1). NV-seeded groundwater aliquots were treated with RNase
before RT-qPCR to quantify only virions with intact capsids
that were potentially infectious (RNase would degrade RNA
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from presumably noninfectious virions with damaged capsids)
(35). RNase-treated NV in groundwater was detected by RT-
qPCR for 1,266 days. Compared to day 0, there was no signif-
icant log10 reduction of NV in RNase-treated water after 427
days, but there was a significant 1.10-log10 reduction of NV in
RNase-treated water by day 1266 of storage (Fig. 1).
Purified NV RNA can remain detectable in groundwater, tap
water, and reagent-grade water for at least 14 days. Purified
NV RNA (extracted from NV virions) was detected by RT-
qPCR in groundwater, tap water, and reagent-grade water for
14 days after seeding (last sampling date) (Fig. 2). Compared
to day 0, there were significant log10 reductions of purified NV
RNA after storage in groundwater for 7 days (0.08-log10 re-
duction) and 14 days (0.09-log10 reduction). Similarly, there
were significant log10 reductions of purified NV RNA after
storage in tap water for 7 days (0.13-log10 reduction) and 14
days (0.25-log10 reduction). Compared to day 0, there were no
significant log10 reductions of purified NV RNA after 14 days
of storage in reagent-grade water.
DISCUSSION
To our knowledge, this is the first study to examine the
long-term infectivity of HuNoV in water. Our results indicate
that NV remains infectious in groundwater for at least 61 days
at room temperature in the dark. This result is supported by
previous infectivity studies of other enteric viruses in water that
have demonstrated the long-term infectivity of poliovirus 3 (at
least 140 days), coxsackievirus B1 (70 days), adenovirus 2 (at
least 364 days) (8), rhesus rotavirus (at least 210 days), and
astrovirus Yuc8 (at least 120 days) (10). Additionally, previous
reports have documented waterborne HuNoV outbreaks
linked with detection of HuNoV in groundwater (4, 14). Our
results are limited by the relatively high dose of NV used to







Duration (range of days postchallenge) of:
Viral sheddinga Clinical symptomsb
0 2/2 Yes/yes NDc/2–13 2–4/2–2
7 2/2 Yes/yes 2–15/5–13 1–4/2–3
14 2/2 Yes/yes 2–22/2–22 2–3/2–3
21 1/4 No/no/yesd/no ND/ND/2–13/ND NAe/NA/2–3/NA
27 1/1 Yes 2–34 2–3
61 2/2 Yes/yes 3–22/4–4 2–3/3–5
a Viral shedding was defined as the presence of NV RNA, detected by RT-PCR, in any postchallenge stool sample.
b Clinical symptoms included diarrhea (2 unformed stools/day), fever (38°C), and vomiting and self-reported nausea, abdominal cramping, headache, myalgia,
and fatigue.
c ND, not detected.
d Corresponds to the 1 infected volunteer at 21 days of stored water.
e NA, not applicable.
FIG. 1. Infectivity and persistence of NV in groundwater. Thirteen genetically susceptible volunteers ingested safety-tested groundwater that
was seeded with 8FIIb NV inoculum and stored for the indicated time points. NV-infected (closed circles) and uninfected (open circles) subjects
at each time point are indicated. Aliquots were analyzed by RT-qPCR, and NV log10 reductions were calculated (number of genomic equivalent
copies/l at each time point [Nt] divided by the average at day 0 [N0]). The triangles (samples without RNase treatment) and squares (samples with
RNase treatment) represent the means of 2 to 5 replicate samples analyzed in duplicate (i.e., 4 to 10 tubes per sample and time point). The break
in the horizontal axis is indicated. Error bars indicate standard deviations. Asterisks correspond to a significant (P  0.05) NV log10 reduction
compared to day 0.
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challenge the subjects (6.5  108 NV GEC) since the inocula
may have remained infectious despite significant NV reduction
throughout storage. To measure the reduction of potentially
infectious NV virions in groundwater over time, we treated
NV-seeded groundwater samples with RNase before RT-
qPCR analysis. This technique detects only NV RNA that is
contained within intact capsids. We observed no significant NV
reduction in RNase-treated samples (containing presumably
infectious NV virions with intact capsids) after 427 days and
only a significant 1.10-log10 reduction after 1,266 days post-
seeding. Because the original dose of NV-seeded groundwater
(6.5  108 NV GEC) caused infection in the study subjects,
the detection of NV in RNase-treated samples at the same
concentration throughout 427 days and a slightly reduced con-
centration by day 1266 suggest that NV may remain infectious
in water for years.
This study evaluated the persistence of HuNoV over the
longest reported storage time to date. NV was detected by
RT-qPCR after storage for 1,266 days in groundwater, with no
significant log10 reduction after 622 days and only a significant
1.79-log10 reduction by day 1266 postseeding. This relative
reduction is significantly larger than the relative reduction ob-
served with RNase-treated samples. This result is expected
since RNA released from damaged viral capsids (detected by
RT-PCR without RNase treatment) is likely more susceptible
to destruction than RNA contained within viral capsids (de-
tected by RT-PCR with RNase treatment). The long-term NV
reduction observed in this study is comparable to our previ-
ously calculated NV nucleic acid reduction rate in groundwater
at 25°C (0.01  0.05 log10/day) (3). In a similar study that used
different HuNoV strains and groundwater samples, Charles et
al. (8) detected HuNoV genogroup I (one of the genetic
HuNoV clusters that includes NV) after 588 days of storage in
groundwater and HuNoV genogroup II after 728 days of stor-
age (their entire study period) with conventional RT-PCR.
Those authors suggest that the long-term HuNoV persistence
in water could result from a HuNoV capsid maturation process
that forms a stable protein coat (demonstrated in murine no-
rovirus but unknown in HuNoV) (8). HuNoV persistence
could also be facilitated by the aggregation of viral particles, a
phenomenon that is observed in natural environments (10).
Furthermore, we hypothesize that the long-term detection of
HuNoV in groundwater by RT-qPCR could partially result
from the long-term persistence of HuNoV RNA. We found
that there was no significant log10 reduction of purified NV
RNA (extracted from NV virions) over 14 days in reagent-
grade water. After 14 days of storage in groundwater and tap
water, there were significant yet relatively small log10 reduc-
tions of purified NV RNA (0.09-log10 reduction in groundwa-
ter and 0.25-log10 reduction in tap water). Although several
studies have examined the stability of HuNoV protein capsids
in various environments (29), this is the first study to examine
the persistence of purified HuNoV RNA in water.
Our specific results on the persistence and infectivity of
HuNoV GI.1 in groundwater should not be generalized to all
types of groundwater or strains and genogroups of HuNoV. As
noted in Materials and Methods, our groundwater samples
were passed through an activated carbon and ion-exchange
resin cartridge to reduce pesticides, meet USEPA drinking
water standards, and safely administer to human subjects.
These water samples were also frozen in aliquots for dose-to-
dose consistency. While it is likely that both treatments
changed the quality of the water compared to an untreated
groundwater sample, our results of persistence of HuNoV in
our groundwater samples were consistent with those of other
published reports (3, 8). As a separate issue, it is likely that
different HuNoV genogroups will exhibit differing levels of
environmental persistence (e.g., water [8] and surfaces [21]),
infectivity (18–20), and resistance to inactivation (7, 13, 15, 28).
Several groups have proposed that differences in environmen-
tal persistence, infectivity, and resistance to inactivation be-
tween the genogroups and strains may be due to differences in
the stability of the HuNoV capsid coat (8), which influence the
viral receptor binding and entry mechanisms of HuNoV (24,
33) (including the contribution of the histoblood group anti-
gens (reviewed in references 31 and 32). These hypotheses may
also explain our unpublished analyses of a systematic review of
900 HuNoV outbreaks (between 1983 and 2010) in which we
found that genogroup I strains, rather than genogroup II
strains, were significantly more likely to be associated with
waterborne outbreaks (data not shown) and that GII-associ-
ated outbreaks had a significantly lower prevalence of food-
borne outbreaks (data not shown) (J. Matthews, B. Dickey, R.
Miller, J. Felzer, B. Dawson, A. Lee, J. Rocks, J. Kiel, J.
Sobolik, J. Eisenberg, C. Moe, and J. Leon, submitted for
publication).
Our finding of the prolonged persistence of infectious
HuNoV in groundwater and the previously reported low in-
fectious dose (50% infectious dose [ID50]) of HuNoV (34)
make HuNoV an important concern for groundwater. Our
study suggests that groundwater supplies contaminated with
HuNoV need to be disinfected or abandoned until future test-
ing indicates sufficient reduction of HuNoV. Due to the long-
FIG. 2. Persistence of purified NV RNA in groundwater, tap water,
and reagent-grade water. Extracted NV RNA was stored in ground-
water, tap water, and reagent-grade water for 14 days. Aliquots were
analyzed by RT-qPCR, and NV log10 reductions were calculated (num-
ber of genomic equivalent copies/l at each time point [Nt] divided by
the average at day 0 [N0]). The triangles (groundwater), squares (tap
water), and circles (reagent-grade water) represent the means of 2
replicate samples analyzed in duplicate (i.e., 4 tubes per sample and
time point). These results are representative of 5 separate experi-
ments. Error bars indicate standard deviations. Asterisks correspond
to a significant (P  0.05) NV log10 reduction compared to day 0 and
are associated with groundwater and tap water at days 7 and 14.
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term persistence of infectious HuNoV in groundwater, short-
term quarantines of HuNoV-contaminated water supplies are
likely to be insufficient for preventing waterborne HuNoV out-
breaks.
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